The Food and Drug Ad­min­is­tra­tion has ap­proved Pralu­ent, the first in an ex­per­i­men­tal class of biotech­nol­ogy drugs,

Modern Healthcare - - LATE NEWS -

which is shown to lower bad choles­terol more sig­nif­i­cantly than older medicines that have been pre­scribed for decades. The drug is ex­pected to gen­er­ate bil­lions in sales for Sanofi and Re­gen­eron Phara­maceu­ti­cals. Pralu­ent is con­sid­ered the first ma­jor ad­vance­ment in heart-dis­ease med­i­ca­tion since the in­tro­duc­tion of statin drugs more than 20 years ago. Still, some ex­perts ques­tion the longterm ben­e­fits of the med­i­ca­tion. Its price tag is also likely to be­come an is­sue, as more scru­tiny is placed on the grow­ing costs of drug ther­a­pies.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.